Quantcast

Latest Paracetamol Stories

2014-06-10 23:00:59

The Firm is investigating Tylenol lawsuits on behalf of patients who allegedly suffered acetaminophen-induced liver damage due to their use of Tylenol-brand over-the-counter medications. New York, New York (PRWEB) June 10, 2014 As Tylenol lawsuits (http://www.tylenollawsuitclaims.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) has issued yet another caution regarding the potential for acetaminophen, the active...

2014-06-09 08:29:12

Data Presented from Company's Pain, Cancer Immunotherapy, and Inappetence Programs KANSAS CITY, Kan., June 9, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced findings from the company's ongoing safety and clinical programs, which were presented at the 2014 American College of Veterinary...

2014-06-03 08:32:29

Multi-Tranche Financing Provides Sufficient Funding to Take KP201 Through and Beyond Potential FDA Approval and Enables KemPharm to Advance its Full Pipeline of Abuse-Deterrent Prodrugs CORALVILLE, Iowa, June 3, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has entered into a $60 million financing agreement with an investment fund managed by...

2014-05-29 08:29:40

MISSISSAUGA, ON, May 29, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that a third party has received U.S. Food and Drug Administration (FDA) approval to market and sell a topical diclofenac sodium 1.5% solution in the United States. The product is a generic version of Nuvo's PENNSAID (diclofenac sodium topical solution) 1.5% w/w (PENNSAID 1.5%). Mallinckrodt Inc. (NYSE:MNK)...

2014-05-29 08:29:06

PITTSBURGH, May 29, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone(®) Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prophylaxis of Plasmodium falciparum malaria and the treatment of...

2014-05-26 23:02:58

The Firm is actively investigating Tylenol liver damage lawsuits on behalf of individuals allegedly injured by acetaminophen, the over-the-counter pain reliever’s active ingredient. New York, NY (PRWEB) May 26, 2014 A number of additional Tylenol lawsuits (http://www.tylenollawsuitclaims.com/ ) alleging liver damage have been filed in a federal litigation currently underway in the U.S. District Court, District of Eastern Pennsylvania over the past month, Bernstein Liebhard LLP reports....

2014-05-23 23:09:43

Ashley Brittain Landers of Schlichter, Bogard & Denton, LLP reports that the FDA has issued a new safety announcement regarding the increased risk of major gastrointestinal (GI) bleeding associated with Pradaxa in comparison to warfarin. The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have been injured after using Pradaxa. St. Louis, MO (PRWEB) May 23, 2014 On May 13, 2014, the FDA issued a Safety...

2014-05-13 16:28:49

- Launched promotional efforts to support Omeclamox®-Pak NASHVILLE, Tenn., May 13, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2014 financial results. During the quarter the Company returned to profitability, launched two new products, and continued to maintain positive cash flow from operations....

2014-05-12 08:31:24

Product is being developed to treat pain in dogs with osteoarthritis KANSAS CITY, Kan., May 12, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the initiation of the pivotal field effectiveness study for AT-001 (grapiprant), the company's innovative drug for treating pain in dogs...

2014-05-07 08:32:56

BUENA, N.J., May 7, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced that it has received tentative approval from the U.S. Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for diclofenac sodium topical solution, 1.5%. http://photos.prnewswire.com/prnvar/20130827/MM70487LOGO Diclofenac sodium topical solution, 1.5% is a nonsteroidal anti-inflammatory drug...